Animal models in peritoneal dialysis research: A need for consensus

Peritoneal Dialysis International

Volumn 25, Issue 1, 2005, Pages 16-24

  Mortier, Siska ^a   Lameire, Norbert H ^a   De Vriese, An S ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Animal models; Biocompatibility

Indexed keywords

ANTIBIOTIC AGENT; HEPARIN; PERITONEAL DIALYSIS FLUID;

BLOOD FLOW VELOCITY; DIALYSATE; FIBROSIS; GENE TRANSFER; HISTOPATHOLOGY; IN VIVO STUDY; MEDICAL RESEARCH; NONHUMAN; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PERITONEUM ADHESION; PERITONITIS; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; STANDARDIZATION;

EID: 15044346715     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500105     Document Type: Review

References (83)

1. Mortier S, De Vriese AS, Van de Voorde J, Schaub TP, Passlick-Deetjen J, Lameire NH. Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 2002; 13:480-9.
2. Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14:1296-306.
3. Zareie M, van Lambalgen AA, De Vriese AS, Van Gelderop E, Lameire N, ter Wee PM, et al. Increased leukocyte rolling in newly formed mesenteric vessels in the rat during peritoneal dialysis. Perit Dial Int 2002; 22:655-62.
4. Jonasson P, Braide M. A commercially available PD fluid with high pH and low GDP induces different morphological changes of rat peritoneum in intermittent PD. Adv Perit Dial 1998; 14:48-53.
5. Zakaria el R, Spain DA, Harris PD, Garrison RN. Generalized dilation of the visceral microvasculature by peritoneal dialysis solutions. Perit Dial Int 2002; 22:593-601.
6. De Vriese AS, Tilton RG, Stephan CC, Lameire NH. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001; 12:1734-41.
7. White R, Ram S. Peritoneal dialysis solution attenuates microvascular leukocyte adhesion induced by nitric oxide synthesis inhibition. Adv Perit Dial 1996; 12:53-6.
8. De Vriese AS, Lameire NH. Intravital microscopy: an integrated evaluation of peritoneal function and structure. Nephrol Dial Transplant 2001; 16:657-60.
9. Menger MD, Richter S, Yamauchi JI, Vollmar B. Intravital microscopy for the study of the microcirculation in various disease states. Ann Acad Med Singapore 1999; 28: 542-56.
10. Wang T, Qureshi AR, Heimburger O, Waniewski J, Bergstrom J, Lindholm B. Daily exposure to dialysis fluid results in changes in peritoneal transport. Perit Dial Int 1997; 17:379-86.
11. Wang T, Heimburger O, Qureshi AR, Waniewski J, Bergstrom J, Lindholm B. Physiological saline is not a biocompatible peritoneal dialysis solution. Int J Artif Organs 1999; 22:88-93.
12. Peng WX, Guo QY, Liu SM, Liu CZ, Lindholm B, Wang T. Comparison of three chronic dialysis models. Adv Perit Dial 2000; 16:51-4.
13. Musi B, Braide M, Wieslander A, Rippe A, Albrektsson A, Henle T, et al. Very high daily intraperitoneal doses of carbonyl compounds affect the morphology, but not the exchange characteristics, of rat peritoneum. Blood Purif 2001; 19:286-92.
14. Slater ND, Cope GH, Raftery AT. Peritoneal ultrafiltration after chronic exposure to dialysis fluid. Perit Dial Int 1992; 12:48-50.
15. Zeltzer E, Klein O, Rashid G, Katz D, Korzets Z, Bernheim J. Intraperitoneal infusion of glucose-based dialysate in the rat - an animal model for the study of peritoneal advanced glycation end-products formation and effect on peritoneal transport. Perit Dial Int 2000; 20:656-61.
16. Park MS, Kim JK, Holmes C, Weiss MF. Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation. Perit Dial Int 2000; 20(Suppl 5):S33-8.
17. Rowe L, Miller TE. Effect of dialysis on the clearance of Staphylococcus epidermidis from the peritoneal cavity: an experimental evaluation. Clin Nephrol 1993; 40:106-13.
18. Findon G, Miller T. Bacterial peritonitis in continuous ambulatory peritoneal dialysis: effect on dialysis on host defense mechanisms. Am J Kidney Dis 1995; 26:765-73.
19. Miller TE, Findon G, Rowe L. Characterization of an animal model of continuous peritoneal dialysis in chronic renal impairment. Clin Nephrol 1992; 37:42-7.
20. Lameire N, Van Biesen W, Van Landschoot M, Wang T, Heimburger O, Bergstrom J, et al. Experimental models in peritoneal dialysis: a European experience. Kidney Int 1998; 54:2194-206.
21. Koksal IT, Usta MF, Akkoyunlu G, Toptas B, Gulkesen KH, Erdogru T, et al. The potential role of advanced glycation end product and iNOS in chronic renal failure-related testicular dysfunction. An experimental study. Am J Nephrol 2003; 23:361-8.
22. Lankisch PG, Koop H, Winckler K, Quellhorst E, Schmidt H. Experimental model for peritoneal dialysis in small laboratory animals. Clin Nephrol 1975; 4:251-2.
23. Kim YL, Kim SH, Kim JH, Kim SJ, Kim CD, Cho DK, et al. Effects of peritoneal rest on peritoneal transport and peritoneal membrane thickening in continuous ambulatory peritoneal dialysis rats. Perit Dial Int 1999; 19(Suppl 2): S384-7.
24. Kim YL, Cho S, Kim JC, Cho DK, Kim YJ, Larm O, et al. Effect in a rat model of heparinized peritoneal dialysis catheters on bacterial colonization and the healing of the exit site. Perit Dial Int 2001; 21(Suppl 3):S357-8.
25. Pawlaczyk K, Garcia-Lopez E, Kuzlan-Pawlaczyk M, Heimburger O, Bergstrom J, Breborowicz A, et al. The effect of icodextrin-based solutions on peritoneal transport in rats undergoing chronic peritoneal dialysis. Perit Dial Int 2001; 21(Suppl 3):S359-61.
26. Suzuki K, Khanna R, Nolph KD, Moore HL, Twardowski ZJ. Effects of bicarbonate dialysis solution on peritoneal transport in rats. Adv Perit Dial 1996; 12:24-6.
27. Wieczorowska K, Khanna R, Moore HL, Nolph KD, Twardowski ZJ. Rat model of peritoneal fibrosis: preliminary observations. Adv Perit Dial 1995; 11:48-51.
28. Wieczorowska-Tobis K, Korybalska K, Polubinska A, Radkowski M, Breborowicz A, Oreopoulos DG. In vivo model to study the biocompatibiLity of peritoneal dialysis solutions. Int J Artif Organs 1997; 20:673-7.
29. Pawlaczyk K, Kuzlan-Pawlaczyk M, Wieczorowska-Tobis K, Polubinska A, Breborowicz A, Oreopoulos D. Evaluation of the effect of uremia on peritoneal permeability in an experimental model of continuous ambulatory peritoneal dialysis in anephric rats. Adv Perit Dial 1999; 15:32-5.
30. Pawlaczyk K, Kuzlan-Pawlaczyk M, Anderstam B, Heimburger O, Bergstrom J, Waniewski J, et al. Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis. Nephrol Dial Transplant 2001; 16:669-71.
31. Wieczorowska-Tobis K, Brelinska R, Breborowicz A, Oreopoulos DG. Morphologic aspects of chronic peritoneal dialysis in a eat model. Perit Dial Int 2001; 21(Suppl 3): S342-4.
32. Wieczorowska-Tobis K, Polubinska A, Wisniewska J, Pawlaczyk K, Kuzlan-Pawlaczyk M, Filas V. Multidirectional approach to study peritoneal dialysis fluid biocompatibility in a chronic peritoneal dialysis modeL in the rat. Nephrol Dial Transplant 2001; 16:655-6.
33. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. New animal models for encapsulating peritoneal sclerosis - role of acidic solution. Perit Dial Int 2001; 21(Suppl 3):S349-53.
34. Imai H, Nakamoto H, Fucshima R, Yamanouchi Y, Ishida Y, Suzuki H. Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis. Adv Perit Dial 2002; 18:124-30.
35. Imai H, Nakamoto H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of adhesion molecules in the progression of peritoneal sclerosis. Adv Perit Dial 2003; 19:180-5.
36. Park SE, Twardowski ZJ, Moore HL, Khanna R, Nolph KD. Chronic administration of iron dextran into the peritoneal cavity of rats. Perit Dial Int 1997; 17:179-85.
37. Pecoits-Filho RF, Twardowski ZJ, Kim YL, Khanna R, Moore H, Nolph KD. The absence of toxicity in intraperitoneal iron dextran administration: a functional and histological analysis. Perit Dial Int 1998; 18:64-70.
38. Lee JH, Reddy DK, Saran R, Moore HL, Twardowski ZJ, Nolph KD, et al. Peritoneal accumulation of advanced glycosylation end-products in diabetic rats on dialysis with icodextrin. Perit Dial Int 2000; 20(Suppl 5):S39-47.
39. Hekking LH, Huijsmans A, Van Gelderop E, Wieslander AP, Havenith CE, van den Born J, et al. Effect of PD fluid instillation on the peritonitis-induced influx and bacterial clearing capacity of peritoneal cells. Nephrol Dial Transplant 2001; 16:679-82.
40. Margetts PJ, Kolb M, Yu L, Hoff CM, Gauldie J. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int 2001; 21(Suppl 3):S368-72.
41. Hekking LH, Aalders MC, Van Gelderop E, Zweers MM, Struijk DG, Havenith CE, et al. Effect of peritoneal dialysis fluid measured in vivo in a rat-model of continuous peritoneal dialysis. Adv Perit Dial 1998; 14:14-18.
42. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Greeuw, I. Better preservation of peritoneal morphologic features and defense in rats after Long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 2001; 12:2775-86.
43. Zareie M, Hekking LH, Welten AG, Driesprong BA, Schadee-Eestermans IL, Faict D, et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18: 2629-37.
44. Zareie M, Hekking LHP, Driesprong BAJ, ter Wee PM, Beelen RHJ, van den Born J. Accumulation of omental mast cells during peritoneal dialysis. Perit Dial Int 2001; 21(Suppl 3):S373-6.
45. Hekking LH, Harvey VS, Havenith CE, van den Born J, Beelen RH, Jackman RW, et al. Mesothelial cell transplantation in models of acute inflammation and chronic peritoneal dialysis. Perit Dial Int 2003; 23:323-30.
46. Zweers MM, Splint LJ, Krediet RT, Struijk DG. ULtrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 2001; 16:651-4.
47. De Vriese AS, Mortier S, Cornelissen M, Palmans E, Vanacker NJ, Leyssens A, et al. The effects of heparin administration in an animal model of chronic peritoneal dialysate exposure. Perit Dial Int 2002; 22:566-72.
48. Mortier S, De Vriese AS, Leyssens A, Vanacker NJ, Faict D, Cornelissen M, et al. Antibiotic administration in an animal model of chronic peritoneal diatysate exposure. Perit Dial Int 2003; 23:331-8.
49. Mortier S, Faict D, Schalkwijk C, Lameire N, De Vriese A. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66:1257-65.
50. Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a Low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 2004 [in press].
51. de Waart DR, Zweers MM, Struijk DG, Krediet RT. Icodextrin degradation products in spent dialysate of CAPD patients and the rat, and its relation with dialysate osmolality. Perit Dial Int 2001; 21:269-74.
52. Gotloib L, Waisbrut V, Shostak A, Kushnier R. Acute and Long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions. Nephron 1995; 70:466-77.
53. Gotloib L, Wajsbrot V, Shostak A, Kushnier R. Effect of hyperosmolality upon the mesothelial monolayer exposed in vivo and in situ to a mannitol-enriched dialysis solution. Nephron 1999; 81:301-9.
54. Ni J, Moulin P, Gianello P, Feron O, Balligand JL, Devuyst O. Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 2003; 14:3205-16.
55. Schambye HT, Flesner P, Pedersen RB, Hardt-Madsen M, Chemnitz J, Christensen HK, et al. Bicarbonate- versus lactate-based CAPD fluids: a biocompatibility study in rabbits. Perit Dial Int 1992; 12:281-6.
56. Di Paolo N, Garosi G, Petrini G, Traversari L, Rossi P. Peritoneal dialysis solution biocompatibility testing in animals. Perit Dial Int 1995; 15(7 Suppl):S61-9.
57. Zweers MM, Douma CE, de Waart DR, van der Wardt AB, Ho-dac-Pannekeet MM, Krediet RT, et al. The standard peritoneal permeability analysis in the rabbit: a longitudinal model for peritoneal dialysis. Perit Dial Int 1999; 19:56-64.
58. Garosi G, Di Paolo N. The rabbit model in evaluating the biocompatibility in peritoneal dialysis. Nephrol Dial Transplant 2001; 16:664-5.
59. Breborowicz A, Knapowski J. Augmentation of peritoneal dialysis clearance with procaine. Kidney Int 1984; 26:392-6.
60. Tran L, Rodela H, Hay JB, Oreopoulos D, Johnston MG. Quantitation of lymphatic drainage of the peritoneal cavity in sheep: comparison of direct cannulation techniques with indirect methods to estimate lymph flow. Perit Dial Int 1993; 13:270-9.
61. Moore H. A chronic catheter model for PD exchanges in the ambulatory rat [Abstract]. Perit Dial Int 1992; 12(Suppl 2):S141.
62. Beelen RH. Role of omental milky spots in the local immune response. Lancet 1992; 339:689.
63. Van Vugt E, Van Rijthoven EA, Kamperdijk EW, Beelen RH. Omental milky spots in the local immune response in the peritoneal cavity of rats. Anat Rec 1996; 244:235-45.
64. De Vriese AS, Mortier S, Lameire NH. Non anticoagulant effects of heparin: implications for animal models of peritoneal dialysis. Perit Dial Int 2001; 21(Suppl 3):S354-6.
65. Krediet RT, Zuyderhoudt FM, Boeschoten EW, Arisz L. Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest 1987; 17:43-52.
66. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11:498-506.
67. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14-27.
68. Lin CY, Chen WP, Yang LY, Chen A, Huang TP. Persistent transforming growth factor-beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence. Am J Nephrol 1998; 18:513-19.
69. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002; 13:721-8.
70. Combet S, Van Landschoot M, Moulin P, Piech A, Verbavatz JM, Goffin E, et al. Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis. J Am Soc Nephrol 1999; 10:2185-96.
71. Suzuki K, Khanna R, Nolph KD, Twardowski ZJ, Moore HL. Expected white blood cell counts and differentials in a rat model of peritoneal dialysis. Perit Dial Int 1995; 15:142-6.
72. Pinto AG, Twardowski ZJ, Nolph KD, Khanna R, Moore HL, Reddy DK. Longitudinal changes in peritoneal membrane transport kinetics in normal rats. Perit Dial Int 1999; 19:72-4.
73. Fracasso A, Baggio B, Ossi E, Del Prete D, Bonfante L, Bazzato G, et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 1999; 33:105-10.
74. Guo W, Willen R, Andersson R, Parsson H, Liu X, Johansson K, et al. Morphological response of the peritoneum and spleen to intraperitoneal biomaterials. Int J Artif Organs 1993; 16:276-84.
75. Martin-Martinez MD, Stoenoiu M, Verkaeren C, Devuyst O, Delporte C. Recombinant adenovirus administration in rat peritoneum: endothelial expression and safety concerns. Nephrol Dial Transplant 2004; 19:1293-7.
76. Stoenoiu MS, De Vriese AS, Brouet A, Moulin P, Feron O, Lameire N, et al. Experimental diabetes induces functional and structural changes in the peritoneum. Kidney Int 2002; 62:668-78.
77. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P, Miyata T, et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001; 12:2146-57.
78. Williams JD, Craig KJ, Von Ruhland C, TopLey N, Williams GT. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl 2003; 88:543-9.
79. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
80. Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S, et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 2001; 16:1262-6.
81. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-36.
82. Margetts PJ, Kolb M, Galt T, Hoff CM, ShockLey TR, Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12:2029-39.
83. Motomura Y, Kanbayashi H, Khan WI, Deng Y, Blennerhassett PA, Margetts PJ, et al. The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-{beta} type II receptor gene transfer. Am J Physiol Gastrointest Liver Physiol 2005; 288:G143-50.